# Caribou Biosciences, Inc. (CRBU) · Edgar & Edgarette company card

> Caribou Biosciences (CRBU) grew revenue 11.7% in FY2025 to $11 million, operating margin -1329% against a -15.8% median for biological products, (no diagnostic substances), equity 69.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1619856 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CRBU) · [JSON](https://www.pops4.com/boards/company/CRBU.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $11M |
| Revenue growth, 1 year | 11.7% |
| Revenue growth per year | 3.8% |
| Operating margin | -1329.4% (prior year -1667.2%) |
| Net margin | -1327.4% |
| Operating cash flow | −$111M |
| Capital spending | $1M |
| Free cash flow | −$112M |
| Cash | $12M |
| Long-term debt | — |
| Total assets | $175M |
| Total equity | $122M |
| Equity ÷ assets | 69.7% |
| Return on equity | -121.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -9.88 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed restructuring or exit costs in the last 12 months; slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -1329.4% in FY2025; revenue is hard to predict: its 80% range is ±85%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $11.2M (FY2025). Experience: revenue up 11.7% on the year, up 3.8% a year over 4 years; operating margin -1329.4%, up from -1667.2%. Soundness: equity 69.7% of assets, return on equity -121.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.2M and $40.1M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.7M to $48.0M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -1329.4% against a -15.8% median; growth 11.7% against 21.4%.

Range logged 2026-10-07, receipt 4dfd39d236d319f4, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-10-06 ([filing](https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-10-06 ([filing](https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000061/0001619856-26-000061-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000060/0001619856-26-000060-index.htm)
- 8-K · filed 2026-10-06 · 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/0001619856-26-000055-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/0001619856-26-000053-index.htm)
- 8-K · filed 2026-06-18 · 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000047/0001619856-26-000047-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001619856.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1619856

## Cite

POPS4, Edgar & Edgarette: Caribou Biosciences, Inc. (CRBU) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/CRBU. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

